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ackground: Genome wide association studies elucidate that IL28B rs12979860 genetic 
polymorphism has a substantial role as a pretreatment predictor during PEG-IFN therapy in 
Hepatitis C virus (HCV) infection, however its role in chronic hepatitis B (CHB) is ambiguous. 
Methods: In this study, we have investigated the role of IL28B variant rs12979860 for chronic hepatitis B 
(CHB) infection. 200 CHB patients were treated for 24 weeks, then we carried out our study on these 
patients. Moreover, all patients were investigated for IL28B rs12979860 genotypes CC, CT, TT through 
RT-PCR. Based on our preliminary results we categorized these patients into two groups i.e. Responder 
R (n = 104) and Non-responderNR (n = 96).  
Results: The proportion of IL28B CC, CT, TT genotypes were in both responder and non-responder 
groups as (72.1%, 25.0%, 2.9% vs 53.1%, 40.6%, 6.2% respectively; P = 0.02). In this study CC was the most 
frequent genotype, which has significant outcome in PEG-IFN therapy in both R and NR groups (72.1% 
vs 53.1%) (P = 0.03), while CT and TT were found as (25.0% vs 40.6%) (P = 0.1, 2.09% vs 6.2%) (P = 0.3) 
respectively. 
Conclusion: Current study clearly demonstrates that IL28B rs12979860 polymorphism is a pretreatment 
predictor during PEG-IFN therapy in CHB infection, and patients with favorable genotype of rs12979860 
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Hepatitis B virus (HBV) is worth considering and 
challenging global health issue in general and Asia in 
particular [1-4]. It has badly effected 02 billion humans 
including 400 million chronically, and claiming the lives 
of 620,000 annually. Likewise, it is prevalent in our 
country (Pakistan) and higher proportion of the 
population is affected (09 million), while it is scaling up 
with each passing day [2,4-9]. Hepatitis B surface 
antigen (HBsAg) persist for more than six months in the 
serum is considered chronic hepatitis B (CHB) infection 
[10,11]. CHB is the leading cause of morbidity and 
mortality in developing countries. It is responsible for 
53% of hepatocellular carcinoma (HCC) and 30% of 
cirrhosis cases [12]. If CHB infection persists up to five 
years it leads to cirrhosis, causing death, yet 15-40% 
cases can be compensated and the rest persist in chronic 
stage. [13,14]. CHB may progress from cirrhosis to 
advance stages HCC and Hepatic Decompensation. 
Approximately 15-20% of CHB patients can progress to 
these serious stages [15-19]. The widespread mortality 
rate is the cause of the close association with the complex 
nature of the virus and host immune system  [20,21].  
Three cytokines (IL28A, IL28B and IL29) have been 
found in the study of GWAS on chromosome no. 19 
(q13), the second mentioned cytokine (IL28B) is coded 
for type ш IFN family and they are IFN-k1, IFN-k2 and 
IFN-k3 which play vital role in generating antiviral 
response by activation of JAK-STAT and MAPK 
pathways [22-24]. The 1st ever study about IL28B was 
reported in 2010, showing IL28B is linked with 
spontaneous clearance in HCV. Whereas, in 2012, the 1st 
influential report about IL28B also showed sustained 
virological response (SVR) in CHB. Furthermore 
Sonneveld reported that IL28B polymorphism has 
significant association in HBeAg seroconversion and 
also increase loss of HBsAg in response to peg IFN [25-
29]. An individual who possesses CC genotypes can give 
better response to the treatment and clear the virus 
rapidly [30]. Li s study containing two groups (healthy 
control and self-limiting the infection) concluded that 
CHB patients had low level of IL28B in their serum, and 
also stated that patients with CC genotypes had higher 
level of IL28B in their serum than the non-CC [31]. 
To prevent the patients from advance stages and to 
stop the progression of liver disease is the ultimate aim 
of the therapy, based on two group of antiviral drugs 
nucleotide analogues (NAs) and IFN. The former 
mentioned having the following drugs (Lamivudine, 
Entecavir, Telbivudine, and two NAs prodrug Tenofovir 
Disoproxil Fumarate, and Adefovir Disoproxil) while 
the later have (conventional IFN and PEGylated IFN) 
[32-35]. Conventional IFN is known as the 1st registered 
drug for the treatment of CHB but has proven ineffective 
due to weak response in patients with normal levels of 
alanine amino transferase (ALT), adverse effects and 
complexity in drug administration. Peg-IFN mediated 
treatment showed remedial steps which eventually leads 
to HBeAg seroconversion and the rendered patients 
with low risk of cirrhosis and HCC [36-40]. In the result 
of phase 3 trials, peg-IFN has turned the axis of interest 
of the researchers and the trials demonstrated that peg-
IFN gives desired results as compared to conventional 
IFN. It is further revealed that unlike NAs, peg IFN 
showing no antiviral resistance because it is given to the 
patient for definite time. Conventional IFN is prescribed 
thrice and peg-IFN one dose per week. Peg-IFN 
suppresses virus significantly, eradicates HBsAg 
satisfactorily and normalizes ALT levels [41-44].  
This study is to understand the role of IL28B gene 
variants in the treatment of peg-IFN in CHB infected 
individuals in Pakistani population.  
Methods 
Patients 
In the present study 355 CHB patients of Pakistani 
origin were included (Figure 1), 155 were dropped due 
to adverse effects of the given therapy, dose negligence 
or missing clinical history. Whereas 200 cases were 
followed on and were given peg-IFN with proper dose of 
180 (million international units per week IM or 
subcutaneously), while the physicians prescribed the 
dose in some patients according to their health 
condition. The selected patients have a complete follow 
up history and they also have completed their 06 month 
regiment of peg-IFN. In these selected cases, 128 were 
males and 72 were females. These patients are 
categorized into two groups as, Responders (R) and 
Non-responders (NR). The inclusion criteria for the 
study are, patients having chronic HBV infection and 
have successfully completed their 06 months of peg-
IFN-Alfa therapy. The patients tested positive for other 
hepatic infections such as hepatitis A, C, D and E, some 
other viral disease or have some other severe medical 
condition were excluded from the study along with 
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pregnant and  women in lactation. The study protocols 
were approved by the ethical committee of Imperial 
College of Business Studies – Faculty of Allied and 
Health Sciences - Lahore. Inform consents were received 
from all the participants of the study. 
 
Figure 1: Flowchart of patient’s selection process 
Laboratory work-up 
For antigen antibody detection serum was used and for 
IL28B genotyping EDTA whole blood was processed. 
Serum was used to investigate co-infections like 
antibody to HDV, HIV, and HCV by a simple technique 
called enzyme linked immunosorbent assay (ELISA). 
HBV DNA was extracted from EDTA blood plasma by 
using FavorPrep TM viral nucleic acid extraction kit by 
strictly following the instruction on the kit. HBV 
quantification was performed on HBV Real Time Quant 
(Sacace Biotechnologies, Como, Italy) on M.J mini 
personal thermo cycler Real time PCR System (BIO-
RAD) use according to the given guidelines. 
IL28B genotyping 
EDTA whole blood samples were used of all the patients 
for the extraction of genomic DNA by using non-
enzymatic salting out protocol. Real time PCR was used 
for the Genotyping of IL28B rs12979860. Proper 
environment was provided to StepOne Biosystem to 
perform amplification. Specific primers i.e. Forward 
primer-1 sequence is 5- AGG GAG CTC CCC GAA 
GGC GC-3 (Forward primer 2 sequence is 5- AGG 
GAG CTC CCC GAA GGC GT-3 (and Reverse primer 
sequence is 5-CCT ATG TCA GCG CCC ACA ATT 
CCC A-3 were used table 2. These primers were 
specifically designed for 190 bp and used for SNP 
rs12979860 genotypes CC, CT, and TT. The reaction 
mixture contained 120-480 ng (2.5 µl) of DNA, 01 µl of 
each primers, 2.5 µl MgCl2, 10X-buffers 2.5 µl, dNTPs 
2.5µl, 0.5 µl of Taq DNA polymerase and nuclease free 
H2O were 12.5l the total volume of the master mix in 
each reaction was 25 l. Thermocycler temperature was 
set as; initial denaturation 95°C for 05 minutes, 
annealing 68°C for 30 seconds and extension 72°C for 30 
seconds. These all steps were programmed in real time 
PCR (StepOne Applied Biosystem).  
Statistical analysis 
SPSS statistic software package version 20.0 was used to 
perform data analysis. Data were analyzed as; qualitative 
variables show frequencies and continuous variables 
were expressed as median and mean. Independent T-
Test was carried out to find the differences in 
frequencies of continuous variables. For qualitative 
variables Pearson chi-square test was used. Hardy 
Weinberg equilibrium is used to find out the 
significance of IL28B polymorphism. 
Results 
HBV genotype A, B, C, and D patients were carried out 
in this study, IL28B genetic polymorphism (rs12979860) 
was investigated in all patients categorized into two 
Groups i.e. Responders (R) and Non-Responders (NR). 
Patients whose viral load were less than 2000 copies 
IU/ml were regarded (R category) n = 104, and those 
patients with more than 2000 copies IU/ml after 
completion of treatment were put into (NR)  category n 
= 96 (Figure 1). Hardy Weinberg equilibrium was 
applied to both categories (R=0.09, NR=0.14). The mean 
± SD age in the R category was (Mean ± SD, 
34.53±11.76) and in NR category (Mean ± SD, 
33.17±07.91) (p = 0.34). The mean ± SD of ALT levels in 
the R category were (Mean ± SD, 67.97±11.02) and in 
NR category (Mean ± SD, 69.53 ± 10.06) (p = 0.29) 
(Table 1). 
Out of 200 cases, males were n = 128 (64.0%) (p 
value=0.28) and in the R category n = 70 (35.0%), and in 
N.R category (n = 58 (29.0%), (p = 0.28) (Figure 2). 72 
females were investigated in a study, R group (n=34) 
(32.7%) and in NR (n=38) (39.6%), (p = 0.63) in both R 
and NR categories. Gender wise (male and female) (p = 
0.31) which is insignificant in response to R and NR 
groups. 
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Figure 2: This figure demonstrates males and females in both 
responder and non-responder groups. 
Figure 4 shows the electrophoresis pattern of IL28B 
(rs12979860) genotypes. In IL28B polymorphism 
(rs12979860) CC genotypes were more frequently in our 
region than non-CC genotypes (Figure 3) i.e. (CC = 
63.0%, CT = 32.5%, TT = 4.5%). CC genotypes were 
abundant in both R (n = 75) (72.1%) and NR (n = 51) 
(53.1%), (p = 0.03) it shows a significant association 
between R and NR groups. Patients with CT genotype 
were (n = 26) (25.0%) in R category, and in NR (n = 39) 
(40.0%) (p = 0.1) which reflects insignificant association 
between R and NR- categories. TT genotype was the 
least frequent genotype in both the categories (R (n = 03) 
(2.9%), NR (n = 06) (6.2%) (p = 0.3).  
 
Figure 3: This shows Distribution of rs12979860 polymorphism 
genotypes. 
 
Figure 4: The electrophoresis pattern 
The IL28B polymorphism (CC CT TT) demonstrated 
significant association in the treatment of peg-IFN 
among the R and NR groups (p = 0.02) (Figure 3). This 
study demonstrates that CC genotype was the most 
frequent genotype in our region and it has a better 
response to peg-IFN therapy in both (R and NR) 
categories compare to CT and TT genotypes. The 
present study did not find any significant variation 
between gender and age wise distribution in both R and 
NR groups. 
Variables Responder (R) Non-responder 
(NR) 
P-value 
Age ± SD 34.53±11.76 33.17±7.91 0.34 
ALT 67.97±11.02 69.53±10.06 0.2 
Gender 
Male 70 (67.3%) 58 (60.4%) 0.2 
Female 34 (32.7%) 38 (39.6%) 0.6 
rs12979860 genotypes 
CC 75 (72.1%) 51 (53.1%) 0.03 
CT 26 (25.0%) 39 (40.6%) 0.1 
TT 03 (2.9%) 06 (6.2%) 0.3 
Total 104 (100%) 96 (100%) 0.02 
Table 1: Demographic profile of responders and non-responders 
IL28B gene Variant                                   Primers 
rs12979860    FP1 AGGGAGCTCCCCGAAGGGGC 
rs12979860    FP2 AGGGAGCTCCCCGAAGGGGT 
rs12979860    RP CCTATGTCAGCGCCCACAATTCCC 
 FP (forwards primer), RP (reverse primer) 
Table 2:  Shows Nucleotide sequence of each primer 
Discussion  
Despite a lot of work in the last few decades to 
understand the nature of the HBV, still many aspects are 
unclear. Numerous safe and effective vaccine are 
available since 1982 yet infection in adults is dilemma 
for the whole population [45-47]. In theory, the ideal 
outcome for the chronic infection is complete 
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elimination of HBV with hepatitis B antigen (HBs) loss, 
seroconversion to anti-HBs and elimination of cccDNA 
(covalently closed circular DNA)  from the infected 
hepatocytes., Yet complete elimination of cccDNA from 
the infected hepatocytes is impossible with any of the 
current antiviral drugs. Similarly in our study, the 
patients were tested for the viral load after the 
completion of therapy, in which most of the patients 
responded to the treatment so significant fall was noted 
in viral load of those patients. [48]. 
Peg-IFN is commonly used antiviral drug to treat 
CHB since 2005 and is almost identical to conventional 
IFN. Recently a lot of work has been done on this 
therapy. It has an important role in suppression of virus 
replication and can lead to HBeAg seroconversion or 
HBsAg clearance, and normalize the serum ALT level 
and reduce the risk of cirrhosis and HCC [39,42-44,49]. 
In last five years peg-IFN has attained interest because 
of the result of phase ш clinical trials. These trails 
demonstrated that peg-IFN therapy has more significant 
result than the standard IFN. These trials also revealed 
that unlike NAs, peg-IFN does not show antiviral 
resistance. Because of the reason that peg-IFN is given 
to the patient for limited time once a week in dose of 
180g leading to high rate of seroconversion. However, 
standard interferon is given to the patient thrice a week 
in a dose of 4.5 million units [41]. In Taiwan 06 months 
of peg-IFN treatment is considered standard treatment 
in CHB infection. Similarly, in current study all the 
participants were treated with peg-IFN for 06 months 
with a dose of 180 g, and in some patients the dose was 
prescribed by the physician according to their health 
conditions [50].  
Genome wide association study shows that three 
cytokines (IL28A, IL28B and IL29) were present on the 
long arm of chromosome no. 19 (q13). Among these 
cytokines IL28B belongs to IFN  family which induce 
the viral responses by stimulating interferon stimulating 
genes (ISGs). In past studies this cytokine was identified 
as main factor of the immune response, which has 
significant association with treatment of CHC infection 
[24,51-58]. Recently on basis of these findings same 
studies were carried out in CHB patients but these 
investigations were not quite conclusive. Solely because 
in CHB it is difficult to predict the most accurate 
biomarker that has a significant outcome in peg-IFN 
therapy [24,55,56]. Many investigations have been done 
to determine the pre-treatment predictor of peg-IFN 
therapy. These observations lead to the fact that peg-IFN 
therapy has effective outcome in those patients who 
have low ALT levels and low viral loads. But clinically 
this predictions are not helpful for therapeutic purposes. 
Limited data was available in past reports in CHB 
infection for the pretreatment prediction of IL28B in 
peg-IFN treated patients, however, few studies have 
predicted that IL28B has an important role in SVR in 
peg-IFN therapy. Based on these findings this 
association gains a lot of interest of the researchers. 
Sonneveld and his colleagues reported that peg-IFN 
therapy had significant outcome in clearance of HBV 
infection by HBeAg seroconversion or  by HBsAg 
clearance [26]. Lampertico investigated 101 HBV 
infected individuals and all were treated with IFN / peg-
IFN therapies, this study revealed that CC genotype 
could give better outcome as compare to non-CC 
genotypes. Thomas in his study also revealed, that 
patients with CC genotype can clear the virus with 
increased rate. These reports demonstrated that IL28B 
as a pretreatment predictor. In line with previous 
studies, we also found rs12979860 CC genotype 
frequently in responder patients than in non-responder 
patients (P = 0.03). Galmozzi conducted meta-analysis 
studies before 2013, he concluded from these set of 
studies that IL28B has significant association in desired 
level result [59,60], while in Mangias report 134 CHB 
infected individuals were investigated, 85% of them have 
HBeAg negative patients and rest were HBeAg positive. 
They all were treated with IFN / peg-IFN for 12-24 
months. Mangia conclusion does not support 
Lampertico and Thomas reports, he stated that IL28B 
(rs12979860) had no influence on HBsAg loss in 
aforementioned therapies [61]. In 2011, a report was 
published in which 609 patients of CHB among Chinese 
Han population were investigated. This report showed 
significant correlation between IL28B polymorphism, 
HBV progression and Hepatic inflammation. This study 
revealed that IL28B genetic polymorphism can prevent 
the viral progression from advance stages and can also 
cure liver inflammation. Furthermore this study also 
revealed that patients who possess CC genotype can give 
the desired level outcome [62]. Later in 2012 another 
report was introduced, in which 205 patients were 
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enlisted from Asian European population. Some 
patients were treated with lamivudine and some were 
with peg-IFN. After investigation for IL28B genotyping 
the proportion of CC, CT, and TT were 77%, 19%, 05%, 
respectively. The author concluded that favorable IL28B 
genotype (rs12979860) can give effective outcome and 
can rapidly lead  to HBeAg seroconversion during peg-
IFN therapy in both Asian and white population [26]. 
Recently a retrospective study (2005-2010) was reported 
on 190 CHB patients and all were treated with peg-IFN 
therapy for tenure of 48 weeks. IL28B (rs12979860) 
genotypes were accounted as CC-47%, CT-36%, and 
TT-15%. This report showed statistically significant CC 
genotype in responder patients ( P = 0.001) after the 
therapy [63]. Another study was conducted (2014) on 
156 Chinese HBV infected population, this study 
resulted that CC genotype (rs12979860) was the most 
frequent genotype compare to other two genotypes (CT 
TT). Furthermore, this report also revealed that patients 
who have CC genotype have elevated IL28B protein level 
which provide defensive contribution to the treatment 
[64]. In Germany a report was published in 2014, in 
which 86 CHB patients were investigated and all were 
treated with peg-IFN. The author concluded that IL28B 
polymorphism has significant prognostic effect in 
treatment of CHB infection [65]. The results of the 
above reports and our current study demonstrated the 
similar outcome. In our current study 200 CHB patients 
were investigated and after investigations they were 
divided into two groups R and NR, patients who 
responded well to peg- IFN therapy and their viral load 
became less than 2000 copies IU/ml were put into R 
(n=104) group, and patients whose response was weak 
to therapy and their viral load were more than 2000 
copies IU/ml were put into NR (n = 96) group. In 
current report the proportion of rs12979860 CC, CT, TT 
genotypes were found in both R and NR groups as; (R = 
72.1%, 25.0%, 2.9% and in NR = 53.1%, 40.6%, 6.2% 
respectively; P = 0.02), on statistical analysis a positive 
association (P = 0.02) were observed in both groups. 
This study has also shown, that CC genotype of IL28B 
(rs12979860) were the most frequent genotype and it has 
better response rate to peg IFN therapy as compared to 
other two genotypes (CT, TT) in this region. 
Furthermore this study also revealed, that TT genotype 
was the least frequent genotype in this region. Non-
significant contribution of age and gender-wise 
distribution was noted in both R and NR groups. This 
study demonstrates the importance of IL28B 
polymorphism (rs12979860) as pretreatment predictor 
in peg-IFN therapy in CHB infection. 
This study depicts that, IL28B rs12979860 variant may 
play role as a predictor of peg-IFN therapy against HBV 
infection. Moreover, this polymorphism may be used as 
a pre-treatment predictor of peg-IFN therapy. The 
results of the current study demonstrate that, CC 
genotype is the most occurring genotype in this region 
and it has a strong association in rapid HBV clearance 
during peg-IFN therapy. According to our hectic 
estimations, efforts need to be carried out on a broader 
and larger cohort of CHB patients to reach the desired 
level results. 200 individuals out of the thick populated 
zone is not enough, as one third of the population is 
victim of HBV. But the nature of this virus is complex so 
we need to evaluate certain more SNPs in order to 
predict accurate pretreatment response of peg-IFN 
therapy. However extra efforts are required to elucidate 
the mechanism involved in this association precisely and 
accurately. 
Conflict of Interest Statement 
The authors declare that there is no conflict of interest 
regarding the publication of this paper. 
References 
1. Idrees M, Khan S, Riazuddin S. Common genotypes of hepatitis 
B virus. Journal of the College of Physicians and Surgeons--
Pakistan: JCPSP, (2004); 14(6): 344-347. 
2. Zhu R, Zhang H-P, Yu H, Li H, Ling Y-Q, et al. Hepatitis B virus 
mutations associated with in situ expression of hepatitis B core 
antigen, viral load and prognosis in chronic hepatitis B patients. 
Pathology-Research and Practice, (2008); 204(10): 731-742. 
3. Ali L, Idrees M, Ali M, Rehman I-u, Hussain A, et al. An 
overview of treatment response rates to various anti-viral drugs 
in Pakistani Hepatitis B Virus infected patients. Virology 
journal, (2011); 8(1): 20. 
4. Li G, Li W, Guo F, Xu S, Zhao N, et al. A novel real-time PCR 
assay for determination of viral loads in person infected with 
hepatitis B virus. Journal of virological methods, (2010); 165(1): 
9-14. 
5. Paraskevis D, Haida C, Tassopoulos N, Raptopoulou M, 
Tsantoulas D, et al. Development and assessment of a novel real-
time PCR assay for quantitation of HBV DNA. Journal of 
virological methods, (2002); 103(2): 201-212. 
6. Alam MM, Zaidi SZ, Malik SA, Naeem A, Shaukat S, et al. 
Serology based disease status of Pakistani population infected 
with Hepatitis B virus. BMC infectious diseases, (2007); 7(1): 64. 
7. Noorali S, Hakim ST, McLean D, Kazmi SU, Bagasra O. 
Prevalence of Hepatitis B virus genotype D in females in Karachi, 




                     Advancements in Life Sciences  |  www.als-journal.com  |  August 2018  | Volume 5  |  Issue 4    17  
 
als 
You’re reading Impact of IL28B gene variants (rs12979860) in peg-IFN therapy against Chronic Hepatitis B Pakistani patients 
 
Pakistan. The Journal of Infection in Developing Countries, 
(2008); 2(05): 373-378. 
8. Hakim S, Kazmi S, Bagasra O. Seroprevalence of hepatitis B and 
C genotypes among young apparently healthy females of 
Karachi-Pakistan. Libyan Journal of Medicine, (2008); 3(2): 66-
70. 
9. Ali M, Idrees M, Ali L, Hussain A, Rehman IU, et al. Hepatitis B 
virus in Pakistan: a systematic review of prevalence, risk factors, 
awareness status and genotypes. Virology journal, (2011); 8(1): 
102. 
10. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. 
Hepatology, (2009); 50(3): 661-662. 
11. Ali Q, Jamal A, Imran M, Ullah S, Kalam I, et al. Correlation of 
IL28B rs12979860 genotype and gender with spontaneous 
clearance of HCV infection: a Pakistani cross-section study. 
Personalized medicine, (2018); 15(6). 
12. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The 
contributions of hepatitis B virus and hepatitis C virus infections 
to cirrhosis and primary liver cancer worldwide. Journal of 
hepatology, (2006); 45(4): 529-538. 
13. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-
negative chronic hepatitis B: natural history and treatment; 2006. 
Copyright© 2006 by Thieme Medical Publishers, Inc., 333 
Seventh Avenue, New York, NY 10001, USA. pp. 130-141. 
14. Saeed MA, Ahmed N, Ali Q. Frequency of Autoantibodies to 
Thyroid Peroxidase (TPO) in Patients with Type 1 Diabetes 
Mellitus. International Journal of Applied Biology and Forensics 
(2018); 2(1): 171-174. 
15. Lee WM. Hepatitis B virus infection. New England Journal of 
Medicine, (1997); 337(24): 1733-1745. 
16. Di Marco V, Iacono OL, Cammà C, Vaccaro A, Giunta M, et al. 
The long‐term course of chronic hepatitis B. Hepatology, (1999); 
30(1): 257-264. 
17. Fattovich G. Natural course and prognosis of chronic hepatitis 
type B. Viral Hepatitis Reviews, (1996); 2: 263-276. 
18. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of 
cirrhosis in patients with chronic type B hepatitis: a prospective 
study. Hepatology, (1988); 8(3): 493-496. 
19. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. 
Hepatitis B–related sequelae: prospective study in 1400 hepatitis 
B surface antigen–positive Alaska native carriers. Archives of 
Internal Medicine, (1990); 150(5): 1051-1054. 
20. Liver EAFTSOT. EASL clinical practice guidelines: Management 
of chronic hepatitis B virus infection. Journal of hepatology, 
(2012); 57(1): 167-185. 
21. Ali Q, Kalam I, Ullah S, Jamal A, Imran M, et al. Predictive value 
of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus 
ribavirin treatment of HCV infection in Pakistani population. 
Personalized medicine, (2018); 15(6): 12. 
22. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer 
S, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. 
Nature immunology, (2003); 4(1): 63-68. 
23. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, 
et al. IFN-λs mediate antiviral protection through a distinct class 
II cytokine receptor complex. Nature immunology, (2003); 4(1): 
69-77. 
24. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et 
al. IL28B is associated with response to chronic hepatitis C 
interferon-α and ribavirin therapy. Nature genetics, (2009); 
41(10): 1100-1104. 
25. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, et al. IL28B 
polymorphism does not determine outcomes of hepatitis B virus 
or HIV infection. Journal of Infectious Diseases, (2010); 202(11): 
1749-1753. 
26. Sonneveld MJ, Wong VWS, Woltman AM, Wong GL, Cakaloglu 
Y, et al. Polymorphisms near IL28B and serologic response to 
peginterferon in HBeAg-positive patients with chronic hepatitis 
B. Gastroenterology, (2012); 142(3): 513-520. e511. 
27. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, 
Takahashi A, et al. A genome-wide association study identifies 
variants in the HLA-DP locus associated with chronic hepatitis 
B in Asians. Nature genetics, (2009); 41(5): 591-595. 
28. Guo Y, Guo H, Zhang L, Xie H, Zhao X, et al. Genomic analysis 
of anti-hepatitis B virus (HBV) activity by small interfering RNA 
and lamivudine in stable HBV-producing cells. Journal of 
virology, (2005); 79(22): 14392-14403. 
29. Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, et al. A 
genome-wide association study of chronic hepatitis B identified 
novel risk locus in a Japanese population. Human molecular 
genetics, (2011); 20(19): 3884-3892. 
30. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. Genetic 
variation in IL28B and spontaneous clearance of hepatitis C 
virus. Nature, (2009); 461(7265): 798. 
31. Hamdan HZ, Ziad AHM, Ali SK, Adam I. Epidemiology of 
urinary tract infections and antibiotics sensitivity among 
pregnant women at Khartoum North Hospital. Annals of clinical 
microbiology and antimicrobials, (2011); 10(1): 2. 
32. Jaroszewicz J. Praktyczne zastosowanie ilościowego oznaczania 
stężeń antygenu HBs. Medical Science Review-Hepatologia,  
1(11): 33-36. 
33. Papatheodoridis GV. Why do I treat HBeAg‐negative chronic 
hepatitis B patients with nucleos (t) ide analogues? Liver 
International, (2013); 33(s1): 151-156. 
34. Perillo R. Benefits and risks of interferon therapy for hepatitis G. 
Hepatology, (2009); 49(5 Suppl): 103-111. 
35. Lampertico P, Viganò M, Colombo M. Why do I treat HBeAg‐
negative chronic hepatitis B patients with pegylated interferon? 
Liver International, (2013); 33(s1): 157-163. 
36. Ono-Nita SK, Kato N, Shiratori Y, Omata M. Current options for 
the therapy of chronic hepatitis B infection. Current infectious 
disease reports, (2001); 3(2): 137-142. 
37. Liaw Y-F, Lin S-M, Chen T-J, Chien R-N, Sheen I-S, et al. 
Beneficial effect of prednisolone withdrawal followed by human 
lymphoblastoid interferon on the treatment of chronic type B 
hepatitis in Asians: a randomized controlled trial. Journal of 
hepatology, (1994); 20(2): 175-180. 
38. Lok AS, Wu P-C, Lai C-L, Lau JY, Leung EK, et al. A controlled 
trial of interferon with or without prednisone priming for 
chronic hepatitis B. Gastroenterology, (1992); 102(6): 2091-
2097. 
39. Sung J, Tsoi K, Wong V, Li K, Chan H. Meta‐analysis: treatment 
of hepatitis B infection reduces risk of hepatocellular carcinoma. 
Alimentary pharmacology & therapeutics, (2008); 28(9): 1067-
1077. 
40. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad 
SD, et al. Long‐term follow‐up of alpha‐interferon treatment of 
                        Advancements in Life Sciences  |  www.als-journal.com  |  November 2018  | Volume 6  |  Issue 1                                                          18  
 
als 
Impact of IL28B gene variants (rs12979860) in peg-IFN therapy against Chronic Hepatitis B Pakistani patients 
 
You’re reading 
patients with chronic hepatitis B. Hepatology, (2004); 39(3): 804-
810. 
41. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, et 
al. Peginterferon α‐2a (40 kDa): an advance in the treatment of 
hepatitis B e antigen‐positive chronic hepatitis B. Journal of viral 
hepatitis, (2003); 10(4): 298-305. 
42. Chan HLY, Leung NWY, Hui AY, Wong VWS, Liew CT, et al. A 
randomized, controlled trial of combination therapy for chronic 
hepatitis B: comparing pegylated interferon-α2b and lamivudine 
with lamivudine alone. Annals of internal medicine, (2005); 
142(4): 240-250. 
43. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, 
et al. Pegylated interferon alfa-2b alone or in combination with 
lamivudine for HBeAg-positive chronic hepatitis B: a 
randomised trial. The Lancet, (2005); 365(9454): 123-129. 
44. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, et al. 
Peginterferon Alfa-2a, lamivudine, and the combination for 
HBeAg-positive chronic hepatitis B. New England Journal of 
Medicine, (2005); 352(26): 2682-2695. 
45. Lacey L. Review of economic benefits of treating chronic 
hepatitis B with lamivudine. Journal of gastroenterology and 
hepatology, (2004); 19(S1): 10-12. 
46. Lavanchy D. Hepatitis B virus epidemiology, disease burden, 
treatment, and current and emerging prevention and control 
measures. Journal of viral hepatitis, (2004); 11(2): 97-107. 
47. for Research EO, Liver EAFTSOT. EASL–EORTC clinical 
practice guidelines: management of hepatocellular carcinoma. 
Journal of hepatology, (2012); 56(4): 908-943. 
48. Liver EAFTSOT. EASL Clinical Practice Guidelines: 
management of chronic hepatitis B. Journal of hepatology, 
(2009); 50(2): 227-242. 
49. Skorka C, Grigorescu-Sido P, Manasia R, Lazăr C, Crişan M. 
EVOLUŢIA HEPATITEI CRONICE VIRALE B LA COPIL SUB 
TRATAMENT CU INTERFERON. Clujul Medical,  852. 
50. Liaw YF, Jia JD, Chan H, Han K, Tanwandee T, et al. Shorter 
durations and lower doses of peginterferon alfa‐2a are associated 
with inferior hepatitis B e antigen seroconversion rates in 
hepatitis B virus genotypes B or C. Hepatology, (2011); 54(5): 
1591-1599. 
51. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer 
S, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. 
Nature immunology, (2003); 4(1): 63-68. 
52. Marcello T, Grakoui A, Barba–Spaeth G, Machlin ES, Kotenko 
SV, et al. Interferons α and λ inhibit hepatitis C virus replication 
with distinct signal transduction and gene regulation kinetics. 
Gastroenterology, (2006); 131(6): 1887-1898. 
53. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et 
al. IL28B genotype is associated with differential expression of 
intrahepatic interferon‐stimulated genes in patients with chronic 
hepatitis C. Hepatology, (2010); 52(6): 1888-1896. 
54. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et 
al. Hepatic ISG expression is associated with genetic variation in 
interleukin 28B and the outcome of IFN therapy for chronic 






55. Ge D, Fellay J, Thompson A, Simon J, Shianna K. rban TJ, 
Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, 
McHutchison JG, Goldstein DB. Genetic variation in IL28B 
predicts hepatitis C treatment-induced viral clearance. Nature, 
(2009); 461(7262): 399-401. 
56. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et 
al. Genome-wide association of IL28B with response to 
pegylated interferon-α and ribavirin therapy for chronic 
hepatitis C. Nature genetics, (2009); 41(10): 1105-1109. 
57. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. Genetic 
variation in IL28B is associated with chronic hepatitis C and 
treatment failure: a genome-wide association study. 
Gastroenterology, (2010); 138(4): 1338-1345. e1337. 
58. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. 
Lambda interferon (IFN-λ), a type III IFN, is induced by viruses 
and IFNs and displays potent antiviral activity against select 
virus infections in vivo. Journal of virology, (2006); 80(9): 4501-
4509. 
59. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, et 
al. IL28B polymorphisms predict interferon‐related hepatitis B 
surface antigen seroclearance in genotype D hepatitis B e 
antigen–negative patients with chronic hepatitis B. Hepatology, 
(2013); 57(3): 890-896. 
60. Galmozzi E, Viganò M, Lampertico P. do interferon lambda 3 
polymorphisms predict the outcome of interferon therapy in 
hepatitis B infection? Authors' reply. Alimentary pharmacology 
& therapeutics, (2014); 39(10): 1251-1252. 
61. Mangia A, Santoro R, Mottola L, Fasano M, Minerva N, et al. 
1331 lack of association between il28b variants and hbsag 
clearance after interferon treatment. Journal of hepatology, 
(2011); 54S525. 
62. Li W, Jiang Y, Jin Q, Shi X, Jin J, et al. Expression and gene 
polymorphisms of interleukin 28B and hepatitis B virus infection 
in a Chinese Han population. Liver International, (2011); 31(8): 
1118-1126. 
63. Boglione L, Cusato J, Allegra S, Esposito I, Patti F, et al. Role of 
IL28-B polymorphisms in the treatment of chronic hepatitis B 
HBeAg-negative patients with peginterferon. Antiviral research, 
(2014); 10235-43. 
64. Shi X, Chi X, Pan Y, Gao Y, Li W, et al. IL28B is associated with 
outcomes of chronic HBV infection. Yonsei medical journal, 
(2015); 56(3): 625-633. 
65. Domagalski K, Pawłowska M, Zaleśna A, Tyczyno M, Skorupa-
Kłaput M, et al. The relationship between IL-28B 
polymorphisms and the response to peginterferon alfa-2a 
monotherapy in anti-HBe-positive patients with chronic HBV 
infection. European journal of clinical microbiology & infectious 
diseases, (2014); 33(11): 2025-2033. 
 
 
This work is licensed under a Creative 
Commons Attribution-Non Commercial 4.0 
International License. To read the copy of this license please visit:  
https://creativecommons.org/licenses/by-nc/4.0/ 
 
